EPRX (Eupraxia Pharmaceuticals) Moat Score : 3/10 (As of Jul. 09, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals Moat Score?

Eupraxia Pharmaceuticals has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Eupraxia Pharmaceuticals has No Moat: Eupraxia Pharmaceuticals Inc has very weak competitive advantages, with limited market share and no significant intellectual property or regulatory barriers. Its R&D capabilities are not yet proven to provide a sustainable moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Eupraxia Pharmaceuticals might have No Moat - Very weak/transient advantages.

Competitive Comparison of Eupraxia Pharmaceuticals's Moat Score

For the Biotechnology subindustry, Eupraxia Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eupraxia Pharmaceuticals's Moat Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Eupraxia Pharmaceuticals's Moat Score falls into.

Save Embed

;

Save Embed

;

Eupraxia Pharmaceuticals (NAS:EPRX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score	Moat Level
10	Wide Moat - Exceptionally dominant and durable wide moat
8 - 9	Wide Moat - Clear and robust wide moat
7	Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6	Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5	Narrow Moat - Solid narrow moat
4	Narrow Moat - Discernible but modest moat
1 - 3	No Moat - Very weak/transient advantages
0	No Moat - No discernible moat

Eupraxia Pharmaceuticals Moat Score Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Eupraxia Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (NAS:EPRX) » Definitions » Moat Score

Comparable Companies

Traded in Other Exchanges

EPRX:Canada

Address

201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4

Website

https://www.eupraxiapharma.com

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.